Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen just bought Rodeo Therapeutics in a move that bolsters its drug candidate pipeline.

Does This First-in-Class Acquisition Make Amgen a Buy?

Amgen caught our attention years ago with strong industry positioning as a leading biotech company, but the risk profile kept position sizing limited. However, the market may have missed how Amgen has de-risked its revenue profile in recent years through acquisition and new product success.

Amgen: Risk Down, Conviction Up

Apple

Adicet Bio, Inc.

Caterpillar

Salesforce

Cisco Systems

Chevron

JPMorgan Chase & Co

Microsoft

Controladora Vuela Cia de Aviacion SAB de CV

Walgreens

Two new breakout stocks for Week 17 with better than 10% short-term upside potential. For only the 2nd time this year, none of the 4 picks broke above 10% this week in the first negative week for the S&P 500 in 5 weeks.

Week 17 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

THOUSAND OAKS, Calif., April 23, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial.

OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

THOUSAND OAKS, Calif., April 22, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the U.S. financial markets.

Amgen Announces Webcast Of 2021 First Quarter Financial Results

Bristol-Myers

Regeneron Pharmaceuticals

Replimune Group Inc

Roche Holding AG

Sanofi

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Analysts See Plenty of Upside for Replimune

PRESS RELEASE:   REGULATED INFORMATION 22 April 2021, 07:01 CEST

Press release Biocartis Group NV: BIOCARTIS Q1 2021 BUSINESS UPDATE

American Express

Home Depot

Honeywell

Coca-Cola

Only a third of the stocks in the Dow rank as industry leaders according to MSCI's ESG rankings. Fortunately, most of those who do also are favored by Wall Street analysts.

The Best ESG Stocks in the Dow

The FDA has granted Breakthrough Therapy Designation to Amgen Inc's (NASDAQ: AMGN) bemarituzumab for patients with gastric and gastroesophageal (GEJ) adenocarcinoma. The designation covers bemarituzumab as first-line treatment of fibroblast growth factor receptor 2b, overexpressing and human epidermal growth factor receptor 2-negative, metastatic and locally advanced GEJ adenocarcinoma in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin).

Amgen's Bemarituzumab Scores Breakthrough Therapy Tag For Gastric, GEJ Cancers

THOUSAND OAKS, Calif., April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal (GEJ) adenocarcinoma in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin), based on an FDA-approved companion diagnostic assay showing at least 10% of tumor cells overexpressing FGFR2b.

Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation

THOUSAND OAKS, Calif., April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™ , a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing.

Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing

East West Bancorp

IAMGOLD

Bancorp

Two new breakout stocks for Week 16 of 2021 with better than 10% short-term upside potential. This past week 1 of 4 stocks beat 10% in less than 5 days with CTRN peaking at +14.1% and closing at 10.2%. The 2 Dow picks were mixed.

Week 16 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

Five Prime Therapeutics

THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash.

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

Citi Trends

Liquidity Services

UnitedHealth Group

Two new breakout stocks for Week 15 of 2021 with better than 10% short-term upside potential. This past week 2 of 4 stocks beat 10% in less than 5 days with CAMT peaking at +10.3% and HIMX +15.7%. The 2 Dow picks gained over +6.7%.

Week 15 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

The shares of Amgen, Inc. (NASDAQ: AMGN) have received a price target increase from $266 to $275 by Oppenheimer. These are the details.

Amgen Stock Price: $275 Target (Up From $266) By Oppenheimer

Amazon

Cooper Companies

Dollar General

McCormick

NextEra Energy

Verizon

Zoetis

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

2020 shows that investors need to be prepared for anything. These eight retirement stocks can do precisely that.

8 Retirement Stocks to Buy for Any Market Conditions

Ideanomics Inc

Ribbon Communications

Two new breakout stocks for Week 14 of 2021 with better than 10% short-term upside potential. This past week FBRX gained over 10% peaking at +14.7%. GNUS also spiked higher before bad reactions to an unclear Marvel deal spiraled into -29% decline.

Week 14 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.

Amgen (AMGN) to Boost Inflammation Pipeline With Rodeo Buyout

The news: Pharmaceutical giant Amgen agreed to acquire Rodeo Therapeutics, a Seattle biotech startup creating small-molecule therapies that help repair and regrow tissues.

Amgen to acquire Seattle biotech company Rodeo Therapeutics for $55M

Oracle

TC Energy

Although these stocks have been underperforming the S&P 500 over the past year, investors shouldn't ignore them.

3 Cheap Stocks to Buy for 2021

With blockbuster immunology treatments Enbrel (via $16 billion acquisition of Immunex in 2009) and Otezla (added in 2013 via $13 billion deal) already in its bag, Amgen Inc (NASDAQ: AMGN) has now put its bet on a privately-held Rodeo Therapeutics. This month, Amgen announced to acquire Five Prime Therapeutics for $1.9 billion and outlasted around 15 potential suitors.

Amgen Bets On Regenerative Immunology With Rodeo Therapeutics Acquisition

THOUSAND OAKS, Calif. and SEATTLE, March 30, 2021 /PRNewswire/ -- Amgen Inc. (NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of multiple tissues.

Amgen to Acquire Rodeo Therapeutics Corporation

Forte Biosciences

Alpha Architect International Quantitative Momentum ETF

Vera Bradley

ViewRay

Two new breakout stocks for Week 13 of 2021 with better than 10% short-term upside potential. This past week one selection gained over 10% with KIRK +16.2% in the early part of the week before giving back all its gains and more.

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

Bayer AG

Cardinal Health

CVS Health

Gilead Sciences

General Mills

Henkel AG & Co KGaA

Novo Nordisk

In the following article, I present 10 recession-proof stocks that are undervalued right now. Including companies from the healthcare sector like Gilead Sciences, Amgen, Novo Nordisk, Walgreens Boots Alliance, CVS Health, Cardinal Health and Bayer.

News for Amgen Stock (AMGN)